The history of tirzepatide: from lab bench to licensed medicine

Where did the idea for a dual-receptor medicine come from?

For most of its early history, the GLP-1 pathway was the main focus for researchers working on appetite regulation and blood-sugar control. GLP-1 agonists like semaglutide showed real clinical promise, but researchers at Eli Lilly were asking a different question: could the GIP receptor, a closely related pathway, add meaningful effect when activated alongside GLP-1?

GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone released in response to eating. Early research suggested that activating both receptors together might produce greater reductions in appetite and body weight than either pathway could achieve alone. The challenge was synthesising a single molecule that bound to both receptors with the right balance of activity. That synthesis work, conducted through the 2000s and early 2010s, eventually produced tirzepatide: a once-weekly injectable peptide with a fatty-acid attachment that extends its half-life and allows for weekly rather than daily dosing.

The resulting molecule was, structurally, something genuinely novel. No approved weight-loss or diabetes medicine had taken this dual-agonist approach before. You can read more about how tirzepatide works today on our tirzepatide overview page.

How did tirzepatide move through clinical development?

Early-phase trials through the 2010s established that tirzepatide was tolerable and produced meaningful reductions in blood glucose and body weight in people with type 2 diabetes. Those results were promising enough to justify a large phase 3 programme.

The SURPASS programme tested tirzepatide in type 2 diabetes across multiple trials. Then came SURMOUNT, the phase 3 programme specifically designed to examine weight management in adults with obesity or overweight. SURMOUNT-1, the flagship trial, randomised 2,539 adults without diabetes to tirzepatide or placebo over 72 weeks. At the highest dose studied, which you can explore further on our tirzepatide l page, average body-weight reduction reached around 20 to 21 per cent, a figure that attracted significant attention from clinicians and regulators alike. The full results were published in the New England Journal of Medicine, and they informed NICE's subsequent appraisal.

The SURMOUNT-5 trial later produced a direct comparison with semaglutide 2.4 mg over 72 weeks, finding that tirzepatide produced greater average weight loss. That evidence sits behind how the two medicines are compared today.

When was tirzepatide licensed in the UK, and what did regulators decide?

The MHRA granted tirzepatide its UK marketing authorisation for weight management in adults — sold under the brand name Mounjaro — building on the SURMOUNT evidence package. The licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment starts at a 2.5 mg weekly dose, which exists primarily to let the body adjust before the prescriber titrates upward through the available strengths, including the tirzepatide 10 mg dose that many patients reach during their titration journey.

NICE published its technology appraisal recommendation for tirzepatide (TA1026) on 23 December 2024, setting out the criteria for NHS use. For private prescribing, the licensed eligibility criteria apply directly. If you are looking at current treatment costs as part of your research, the Mounjaro price page explains what private treatment typically involves.

The Black Triangle designation reflects the fact that, as a relatively new medicine, tirzepatide is subject to intensified monitoring. The MHRA encourages patients to report any suspected side effects through the Yellow Card scheme, which is how post-marketing safety data continues to be collected. That monitoring is an ordinary part of how new medicines are managed in the UK, not a signal of unusual risk.

What does tirzepatide's regulatory history mean for patients starting treatment now?

By the time a patient receives their first Mounjaro pen, the medicine behind it has been through years of preclinical work, multiple large randomised trials, and scrutiny from both the MHRA and NICE. That history matters practically: prescribers, including those at our clinical team, are working with an evidence base that now covers thousands of trial participants and growing real-world data.

It also means the treatment pathway is well-established. Doses, titration schedules and monitoring expectations are documented in the NICE appraisal of tirzepatide (TA1026) and in the medicine's summary of product characteristics, which also covers higher maintenance doses such as tirzepatide 30 mg for patients who titrate to that level. Patients can start with confidence that the clinical infrastructure around this medicine is solid.

One practical note: if you are thinking about starting a new treatment and timing matters to you, orders placed by midday on a working day go through same-day clinical review. Christmas week and bank holidays aside, that rhythm holds reliably throughout the year.

If you have questions about whether tirzepatide is appropriate for your circumstances, our prescribers are the right people to ask. You can speak to our prescribers through a free consultation and get a personal assessment the same day.